86 related articles for article (PubMed ID: 694483)
1. A new basis for treatment of multiple myeloma.
Salmon SE; Durie BG; Hamburger AW
Schweiz Med Wochenschr; 1978 Oct; 108(41):1568-72. PubMed ID: 694483
[TBL] [Abstract][Full Text] [Related]
2. In vitro cloning and chemosensitivity of human myeloma stem cells.
Salmon SE
Clin Haematol; 1982 Feb; 11(1):47-63. PubMed ID: 6176384
[No Abstract] [Full Text] [Related]
3. [New aspects in the clinical course determination and therapy in multiple myeloma].
Ludwig H; Pietschmann H
Acta Med Austriaca; 1979; 6(5):255-60. PubMed ID: 555224
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.
Salmon SE; Hamburger AW; Soehnlen B; Durie BG; Alberts DS; Moon TE
N Engl J Med; 1978 Jun; 298(24):1321-7. PubMed ID: 77475
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease.
Hungria VT; Latrilha MC; Rodrigues DG; Bydlowski SP; Chiattone CS; Maranhão RC
Cancer Chemother Pharmacol; 2004 Jan; 53(1):51-60. PubMed ID: 14574458
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)].
Bataille R; Morlock G; Rosenberg F; Sany J; Serre H
Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels and clinical significance of soluble CD86 in myeloma patients.
Hock BD; Drayson M; Patton WN; Taylor K; Kerr L; McKenzie JL
Br J Haematol; 2006 Apr; 133(2):165-72. PubMed ID: 16611307
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
Bettini R; Tonolini M; Bernasconi M
Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
11. Nitrosoureas in multiple myeloma.
Salmon SE
Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701
[TBL] [Abstract][Full Text] [Related]
12. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
[TBL] [Abstract][Full Text] [Related]
13. [Determination of the tumor cell mass and its significance as a parameter for prognosis and therapy in patients with multiple myeloma].
Ludwig H; Schneider K; Pietschmann H
Acta Med Austriaca; 1978; 5(4-5):164-6. PubMed ID: 756132
[TBL] [Abstract][Full Text] [Related]
14. Individualized chemotherapy in multiple myeloma by cytostatic drug sensitivity testing of colony-forming stem cells.
Ludwig H; Fritz E
Anticancer Res; 1981; 1(6):329-34. PubMed ID: 7344610
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
16. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
17. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
18. Cellular kinetics in multiple myeloma. A new approach to staging and treatment.
Salmon SE; Durie BG
Arch Intern Med; 1975 Jan; 135(1):131-8. PubMed ID: 1089396
[TBL] [Abstract][Full Text] [Related]
19. Remission maintenance therapy for multiple myeloma.
Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine.
Hofmann V; Salmon SE; Durie BG
Blood; 1981 Sep; 58(3):471-6. PubMed ID: 7259835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
